Skip to content

To evaluate the effect of leech therapy and ointment in the management of ringworm

A Comparative Clinical Study To Evaluate the Efficacy of Irsal-E-Alaq (Leech Therapy) And Marham-E-Quba in the Management of Quba (Dermatophytosis) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072206
Enrollment
40
Registered
2024-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Leech therapy: No. of leech will be applied on the basis of affected area. One or more leech will be applied on each affected area.Duration variable because its depend upon the sucking

Sponsors

State unani medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically Diagnosed patients of Quba on the basis of signs & symptoms and positive KOH examination. 2. Age group 18-60 years. 3. Patients of both genders. 4. Patients not taking any other drugs for Quba. 5. No apparent pathology of the skin. 6. Patients who are willing to sign informed consent. 7. Patient who would be agree to sign the informed consent and follow the protocol.

Exclusion criteria

Exclusion criteria: 1. Patients below the age of 18 years and above the age of 60 years. 2. Pregnant and lactating women. 3. Known case of bleeding disorder and anaemia. 4. Known case of acute infection and septicaemia. 5. Known cases of severe concomitant skin disease like- Psoriasis, Eczema, impetigo, erysipelas, pityriasis rosea etc. 6. Patient on immuno-compromised drugs. 7. Known cases of severe systemic & metabolic diseases like- Diabetes Mellitus, Hypertension, Hepatitis B, Hepatitis C, and HIV. 8. Any allergy positive patient will be excluded. 9. Non-compliance with the study protocol. 10. Obese patient. 11. Patients who do not want to give their consent for study.

Design outcomes

Primary

MeasureTime frame
1.Pruritus 2.Erythema 3.Size of lesion 4.Number of lesion 5.ScalingTimepoint: 0, 7, 14, 21, 28 Days

Secondary

MeasureTime frame
1.KOH mount 2.Dermatology Life Quality IndexTimepoint: 0, 28 days

Countries

India

Contacts

Public ContactJunaid Taseen

State Unani Medical College, Prayagraj

drjamalakhtar@yahoo.com8052142175

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026